Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
about
Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsInhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatmentInterferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsHow type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Interferons: Success in anti-viral immunotherapy.Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Treatment recommendations for chronic myeloid leukemiaCo-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Do we need more drugs for chronic myeloid leukemia?Update on emerging treatments for chronic myeloid leukemia.IFNA2: The prototypic human alpha interferon.Minimal Residual Disease Eradication in CML: Does It Really Matter?Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.Type I Interferons and Natural Killer Cell Regulation in Cancer.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.Suppression of Transposable Elements in Leukemic Stem Cells.A critical history of chromic myeloid leukemiaDasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments.The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
P2860
Q26771790-0B7F5AEA-FDF5-4F44-9158-5E4178AA6A27Q26849792-FEC47393-9E9C-459D-9191-39193C254F43Q28541451-520674B2-C5D3-420D-9DC0-CCD01ACDA3D5Q28552307-8FC561F6-2CDB-43A0-B3A1-135EEAF70D9BQ33988240-FAE81C81-A220-46B8-8B32-513422BC455DQ34055591-F50848BD-3D81-4EDB-8ACB-4993CF07CCF3Q34276038-BF1415EC-E712-4178-926F-1C6D6BC4C8BAQ35051508-D5D668DA-C98D-4AD8-A69C-85C4861BAF4FQ35931271-C0302A22-5A77-4705-B60D-7F389E0BB0A4Q36540171-D986CDD3-7666-45A1-948D-9779C841DC45Q37026032-414AA874-03D3-4B3A-A4B8-6CB35A96DB45Q37513066-B9B07E25-1300-4E51-93AD-E3404AD08C81Q38167808-5D44F8F6-5B46-48CE-9573-A74BA08C24ACQ38181112-73D91B1F-6184-4B38-8E5B-E93354A0356BQ38193659-FB2DA157-DF12-40BA-B65C-2D98843FD5ACQ38289033-41CAC808-FB3B-414B-BD11-4F75B6104061Q38397515-98DA32A9-3357-476F-9D6E-660CC796AF77Q38486383-C5B6CED9-71F2-4C55-97A2-3ACEFC1644B7Q38602633-F61C91B1-4B8A-4034-B341-388F66C0AA92Q39028177-CAB78292-998F-4D0F-B42E-4542FBB713D6Q39241784-FABAB2F4-46D3-4346-9184-874EEE62AF49Q39411920-6E947EEA-EC56-4A89-BFF4-084B25DA8EB5Q39924810-7B696366-B090-4BFC-820A-FFE8C18CC553Q40007199-BCA96AB1-268F-4191-B70E-C70C5D07C163Q40098712-BA268B2D-A0B3-48FB-9975-5FB6B03845DDQ41877378-BC8C2855-39DF-4DA1-883B-8F32D6E8C770Q42650776-A6EA50E3-7194-4919-85E9-416D52C5DF6DQ42694242-3A4A80B0-6D98-41B8-ADF5-3F63252C275DQ47917650-CF550728-7B48-4CF3-A1C7-88732AA7DE7AQ47980151-8E152BAE-A9DB-44A5-8E65-B712C07A4CF7Q48147441-CA6DAC18-7CC9-4CEA-8093-5F30CFA3327EQ50896731-8CBF04D5-98A8-4D71-A66B-8AB7D4F05CFFQ55396890-3DE5BC2E-5CCF-4FFE-B37A-D2EA9344DC5DQ58449026-D9E3D540-D576-4FEB-A4A6-5F6FF1DCE8EA
P2860
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
@en
type
label
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
@en
prefLabel
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
@en
P2093
P2860
P921
P356
P1433
P1476
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
@en
P2093
A Quintás-Cardama
R Hehlmann
P2860
P2888
P304
P356
10.1038/LEU.2012.313
P5008
P577
2012-11-07T00:00:00Z
2013-04-01T00:00:00Z